Allergan's Migraine Treatment Approved by FDA
December 23 2019 - 3:33PM
Dow Jones News
By Dave Sebastian
The Food and Drug Administration said it has approved Ubrelvy,
Allergan PLC's (AGN) migraine tablets.
Allergan USA Inc., an Allergan entity, tested Ubrelvy's
performance on the treatment of migraine in adults in two trials
involving 1,439 patients with a history of migraine, with or
without visual disturbance, the agency said Monday.
The agency said the proportion of patients who had reduced
headache two hours after treatment was greater in those who took
Ubrelvy than those who took the placebo. There was also a larger
proportion of patients whose migraine symptoms such as nausea and
light sensitivity stopped two hours after treatment with Ubrelvy,
FDA said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
December 23, 2019 15:18 ET (20:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
